

Biota Holdings Limited

ACN 006 479 081

10/585 Blackburn Road
Notting Hill VIC 3168
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au

For Immediate Release

Melbourne, Australia — 3 August 2011

Dr John Domagala joins Scientific Advisory Board

Biota Holdings Limited (ASX:BTA) is pleased to announce that Dr John Domagala has agreed to join its Scientific Advisory Board (SAB).

Dr Domagala has over 30 years of experience in pharmaceutical anti-infective research and has held senior management positions in the US pharmaceutical industry. His former roles included Executive Director Infectious Diseases, Pfizer Global Research and Senior Director Warner-Lambert/Park Davis. During his career he has led multi-disciplined project teams in every aspect of drug discovery and development with successful progression of 10 prospective drugs into clinical development and 3 New Drug Applications. He has a PhD in medicinal chemistry and commercial experience encompassing early to late discovery stage projects through to full clinical development including an in depth understanding of market needs and trends, as well as all aspects of preclinical safety and pharmacokinetic assessments.

Dr Domagala has previously advised Biota including during the acquisition of the assets of Polysis. Biota expects to benefit substantially from his knowledge and experience as a standing member of the SAB.

The appointment builds upon the world class stature of Biota's SAB and to the extent that it is possible, addresses the loss of Prof Morris Robbins who tendered his resignation and notice of intended retirement at the last meeting. The Company extends its appreciation to Prof Robbins for his contributions to the SAB over his many years of association with Biota.

Biota considers a strong well balanced and independent SAB to be an important part of our R&D infrastructure. It provides ongoing oversight to our R&D through an appropriately qualified and experienced team of experts. The next annual meeting of Biota's SAB will be held in London, UK during August 2011.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product Inavir[®], is approved for marketing in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza[™] is a registered trademark of the GlaxoSmithKline group of companies.
Inavir[®] is registered to Daiichi Sankyo.

Investor / Analyst Enquiries

Biota Holdings Limited

Peter Cook
T: +61 3 9915 3720
Damian Lismore
T: +61 3 9915 3721

Media Enquiries

Nerida Mossop, Hinton & Associates
T: +61 3 9600 1979 / M: +61 437 361 433

US Enquiries

Hershel Berry, Blueprint Life Science Group
M: +1 415 505 3749